Video Experimental Relacionado
Updated: Feb 22, 2026
08:31
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.6K
Conferencia de la Comunidad de Farmacología de Sistemas Abiertos (OSP-CC) Procedimientos 2025
Henrik Cordes1, Pieter Annaert2, Pavel Balazki3
1Research Pharmacometrics, Sanofi R&D, Frankfurt am Main, Germany.
CPT: pharmacometrics & systems pharmacology
|February 21, 2026
Resumen
El Open Systems Pharmacology (OSP) Suite, software gratuito de código abierto, está avanzando en el desarrollo de medicamentos basados en modelos (MIDD) a través de la colaboración de la comunidad. Los últimos avances fueron compartidos en la Conferencia de la Comunidad de la OSP (OSP-CC) en París.
Área de la Ciencia:
- Farmacología Farmacología.
- Biología computacional Biología computacional.
- Ingeniería de software Ingeniería de software.
Sus antecedentes:
- PK-Sim y MoBi, desarrollados por Bayer Technology Services, se convirtieron en el Open Systems Pharmacology (OSP) Suite.
- La OSP Suite fue lanzada como software libre y de código abierto en 2017.
- Una comunidad internacional activa de la academia, la industria y las partes interesadas regulatorias impulsa su mejora continua.
Objetivo del estudio:
- Para resumir los avances recientes en el desarrollo de fármacos basados en modelos de código abierto (MIDD).
- Para resaltar los avances presentados en la segunda Conferencia de la Comunidad OSP (OSP-CC).
Principales métodos:
- La OSP Suite facilita el desarrollo de fármacos basado en modelos (MIDD).
- El desarrollo y la colaboración impulsados por la comunidad son fundamentales para su avance.
- La Conferencia de la Comunidad OSP sirvió como una plataforma para el intercambio de conocimientos.
Principales resultados:
- La OSP Suite ha fomentado un entorno de colaboración para MIDD.
- El segundo OSP-CC convocó con éxito a más de 100 expertos de más de 40 instituciones.
- Se mostraron las mejoras y avances continuos en la OSP Suite.
Conclusiones:
- La OSP Suite es un valioso recurso de código abierto para acelerar el desarrollo de medicamentos.
- El compromiso de la comunidad es crucial para el éxito continuo y la evolución de la OSP Suite.
- Se esperan avances futuros en MIDD a través de la colaboración continua de código abierto.
Videos de Conceptos Relacionados
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
01:28Biopharmaceutics and Pharmacokinetics: Overview
4.4K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.4K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
24
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
337
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
337
01:21Pharmacodynamics: Overview and Principles
3.5K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.5K
01:29Pharmacogenetics and Pharmacogenomics: Overview
46
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
46